Plain-English translation of NCT05999240 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing whether a medication called pimavanserin can help reduce rigid thinking patterns and repetitive behaviors in people with autism spectrum disorder. Researchers want to understand if this medication is safe and whether it actually works to make daily life more flexible. The study will involve about 30 teenagers and adults at two research sites.
Many people with autism experience rigid thinking and repetitive behaviors that can make daily life challenging. Currently, there are limited medications specifically designed to help with these symptoms, so researchers are testing this medication to see if it offers a new treatment option.
You likely qualify if…
You likely don't qualify if…
You would start by attending screening visits where clinicians assess whether you're a good fit for the study. Then, you'd enter a crossover phase where you randomly receive either the medication or a placebo (sugar pill) in identical-looking capsules—neither you nor the researchers will know which one you're taking. After completing this phase, you'd move into an open-label period where you take the actual medication for six weeks. Throughout the study, you and your caregiver would complete check-ins and rating scales to track how you're doing, and you'd continue any other treatments you're currently using.
AI-generated summary from trial data · Jun 8, 2026 · Not medical advice
United States